{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:28:55Z","timestamp":1792114135641,"version":"4.4.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To compare the short-term financial costs of treating a patient in myasthenia gravis crisis with intravenous immunoglobulin (IVIG) versus plasma exchange.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>An itemized comparative cost-minimization analysis of IVIG versus plasma exchange for myasthenia gravis crisis was performed. Calculations were based on each therapy's implementation cost, associated hospitalization times, and predicted cost to treat known complications. A cost superiority determination was proposed based on the total cost profile of each therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The difference in total cost favored IVIG over plasma exchange with an average savings of $22,326 per patient. Sensitivity analysis demonstrated that overall costs are highly dependent on IVIG dosing, hospital lengths of stay, and the number of plasma exchange days required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The use of IVIG for myasthenia gravis crisis may be a short-term cost minimizing therapy compared with plasma exchange. Additional prospective studies are required to evaluate the extended cost profile and efficacy of these therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cnd.0b013e31822c34dd","type":"journal-article","created":{"date-parts":[[2011,11,19]],"date-time":"2011-11-19T04:23:03Z","timestamp":1321676583000},"page":"85-94","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":51,"title":["Plasma Exchange versus Intravenous Immunoglobulin for Myasthenia Gravis Crisis: An Acute Hospital Cost Comparison Study"],"prefix":"10.1097","volume":"13","author":[{"given":"Chad","family":"Heatwole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Noyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20240808","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000279334","article-title":"The incidence of myasthenia gravis: a systematic literature review.","volume":"34","author":"McGrogan","year":"2010","journal-title":"Neuroepidemiology"},{"key":"R2-3-20240808","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","article-title":"Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals.","volume":"72","author":"Alshekhlee","year":"2009","journal-title":"Neurology"},{"key":"R3-3-20240808","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/mus.21433","article-title":"3rd, et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee.","volume":"40","author":"Donofrio","year":"2009","journal-title":"Muscle Nerve"},{"key":"R4-3-20240808","first-page":"CD002275","article-title":"Plasma exchange for myasthenia gravis.","volume":"4","author":"Gajdos","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"R5-3-20240808","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1046\/j.1526-0968.2000.004004291.x","article-title":"The six year experience of plasmapheresis in patients with myasthenia gravis.","volume":"4","author":"Chiu","year":"2000","journal-title":"Ther Apher"},{"key":"R6-3-20240808","first-page":"1","article-title":"Natl Inst Health Consens Dev Conf Consens Statement.","volume":"6","year":"1986","journal-title":""},{"key":"R7-3-20240808","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial.","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"key":"R9-3-20240808","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group.","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"R10-3-20240808","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1046\/j.1525-1594.2001.06717.x","article-title":"Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis.","volume":"25","author":"Ronager","year":"2001","journal-title":"Artif Organs"},{"key":"R11-3-20240808","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1212\/WNL.52.3.629","article-title":"Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis.","volume":"52","author":"Qureshi","year":"1999","journal-title":"Neurology"},{"key":"R12-3-20240808","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ana.22139","article-title":"Comparative analysis of therapeutic options used for myasthenia gravis.","volume":"68","author":"Mandawat","year":"2010","journal-title":"Ann Neurol"},{"key":"R13-3-20240808","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group.","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"R14-3-20240808","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","article-title":"Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial.","volume":"62","author":"Gajdos","year":"2005","journal-title":"Arch Neurol"},{"key":"R15-3-20240808","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1212\/01.WNL.0000068335.01620.9D","article-title":"The clinical features of 16 cases of stroke associated with administration of IVIg.","volume":"60","author":"Caress","year":"2003","journal-title":"Neurology"},{"key":"R16-3-20240808","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1473-0502(03)00120-4","article-title":"Plasma exchange in France: epidemiology 2001.","volume":"29","author":"Korach","year":"2003","journal-title":"Transfus Apher Sci"},{"key":"R17-3-20240808","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2165\/00019053-200624100-00009","article-title":"The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US.","volume":"24","author":"Sullivan","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"R18-3-20240808","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/ei\/cbh042","article-title":"The value of life: estimates with risks by occupation and industry.","volume":"42","author":"Viscusi","year":"2004","journal-title":"Economic Inquiry"}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00131402-201112000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:23:49Z","timestamp":1786047829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00131402-201112000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0b013e31822c34dd","relation":{},"ISSN":["1522-0443"],"issn-type":[{"value":"1522-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}